Clinical Observation Of Different Chemotherapy Regimens For Patients With Recurrent Ovarian Cance

Objective: Along with the change of living condition, the diet and the environment, more and more women died of ovarian cancer. The relevant data statistics prove that the death rate of ovarian cancer is much higher in gynecological tumors. In clinical, the main treatm ent method of recurrent ovarian cancer is chemotherapy. This research explores the reasonable regimens for recurrent ovarian cancer by analyzing the three different chemotherapy regimens for treatment of recurrent ovarian cancer clinical efficacy and safety.Methods: The research collected 90 patients with recurrent ovarian cancer in the Qinghai University Affiliated Hospital from April 2013 to April 2014. According to different chemotherapy regimens, patients were divided into Group A: 30 cases, gemcitabine 1000 mg / m2, d1, d8; cisplatin 75 mg / m2, d1, d8,21 d for 1 cycle, Group B: 30 For example: Irinotecan 60 mg / m2, d1, d8, d15; cisplatin 60 mg / m2, d1,28 d days for a cycle and Group C: 30 For example: paclitaxel 135-175 mg / m2, carboplatin 300 mg, d1,21 d for one cycle. The research compared the efficacy and safety of the chemotherapy regimens for ovarian cancer recurrence by adopting the above three different chemotherapy.Results: The chemotherapy efficiency of the three groups was respectively 50%,50%, 46.7%, and clinical benefit rate was 76.7%, 80%, 83.3%, there was no significant difference to three groups(P >0.05). All patients in the three groups could tolerate the side effects of chemotherapy toxicity. Among them, the incidence rates is group A thrombocytopenia Ⅲ, Ⅳ, accounting for 10%, group B with a greater incidence of diarrhea Ⅱ, Ⅲ, accounting for 40%, and group C high incidence of alopecia Ⅱ, Ⅲ, accounting for 66.7%.Conclusions: The effective rate of gemcitabine + cisplatin chemotherapy is 50% and 76.7%. The clinical benefit rate is 80%. Paclitaxel + Kappa group efficiency is 46.7%. There was no remarkable difference compared with three sets of results, not statistically significant. Th is study proved that different chemotherapy regimens on recurrent ovarian cancer could have very good result, and side effect could be tolerated.